Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI(R) Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

SAN DIEGO, Oct. 22, 2019 -- (Healthcare Sales & Marketing Network)-- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of th...Biopharmaceuticals, Oncology, FDA
Heron Therapeutics, CINVANTI, aprepitant, Emetogenic Chemotherapy, Chemotherapy